Profile of antiretroviral and its outcome on patients with HIV-AIDS in Wamena Public Hospital


Published: 29 March 2019
Abstract Views: 862
PDF: 344
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

In Papua, HIV/AIDS is characterized as a widespread epidemic, with a prevalence of 2.3% and a case rate of 416.91 per 100.000. The low accessibility of healthcare services is a major challenge for health services in Papua. The purpose of this study was to determine the profile of ARV use and therapy outcomes of HIV/AIDS patients at Wamena Public Hospital in Papua. This research is an observational cross-sectional retrospective study. Data was collected from the medical records of 236 patients who met the inclusion criteria. Study showed that FDC (TDF + 3TC + EFV) is the most frequently used ARV. ARV therapy improved the clinical condition of 14 patients, and 9 patients had a worsening of their clinical condition. There was an increase in CD4 cell count after 6, 12, and 24 months of ARV therapy in 76%; 55%; and 72% of patients. There were 55 adverse drug events that required a change of regimen. Based on this study, the use of antiretroviral drugs improved clinical condition, decreasing the number of IO, and increasing the patient's CD4 cell count.


Triyono, E. A., Seran, S. R., & Hasmono, D. (2019). Profile of antiretroviral and its outcome on patients with HIV-AIDS in Wamena Public Hospital. Dermatology Reports, 11(s1). https://doi.org/10.4081/dr.2019.8063

Downloads

Download data is not yet available.

Citations